New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For LLY;PFE;ACTC;CYTX;STEM;ATHX;LH;OVSC;NBS;PSTI;FLDM From The Last 14 Days
Check below for free stories on LLY;PFE;ACTC;CYTX;STEM;ATHX;LH;OVSC;NBS;PSTI;FLDM the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | all recent news | >>
September 29, 2014
20:01 EDTPFEPfizer, Kyowa Hakko Kirin to collaborate on immuno-oncology combination study
Pfizer and Kyowa Hakko Kirin announced that they have entered into an agreement to explore the therapeutic potential of the combination of Pfizerís PF-05082566, an investigational, fully humanized monoclonal antibody that stimulates signaling through 4-1BB, a protein involved in regulation of immune cell activation, proliferation and survival, with Kyowa Hakko Kirinís anti-CCR4 antibody mogamulizumab, which suppresses some of the immune cells that shield the tumor from the immune system, in a Phase Ib clinical study evaluating the safety and tolerability of the combination in patients with solid tumors. Under the terms of the agreement, Pfizer and Kyowa Hakko Kirin will co-fund the clinical study, which will be conducted by Pfizer. This study is expected to establish a recommended dose regimen and assess the safety and preliminary efficacy of the combination. This study is expected to begin in 2015 and the results will determine the future clinical development of the combination.
07:26 EDTPFEInforma Business Information to hold a conference
Subscribe for More Information
06:45 EDTLHLabCorp removed from short-term buy list at Deutsche Bank
Subscribe for More Information
September 28, 2014
16:29 EDTPFEPfizer's Xalkori shrunk tumors in patients with genetic mutation, Bloomberg says
Subscribe for More Information
September 26, 2014
16:55 EDTPFEMarket ends week lower after inversion crackdown, mixed data
Subscribe for More Information
10:09 EDTLHHigh option volume stocks
Subscribe for More Information
09:05 EDTPFEGlycoMimetics announces delay in initiation of Phase e trial with rivipansel
Subscribe for More Information
September 25, 2014
09:13 EDTLHOn The Fly: Pre-market Movers
HIGHER: LipoScience (LPDX), up 63% after agreeing to be acquired by LabCorp (LH) for $5.25 per share in cash... Magnum Hunter (MHR), up 12.5% after announcing that throughput volumes on Eureka Hunter's gas gathering pipeline system have increased to about 316,500 MMBtu per day... Jabil Circuit (JBL), up 4.7% following its report of better than expected fourth EPS and revenue... JD.com (JD), up 0.7% after the stock was initiated with an Outperform rating at Macquarie. LOWER: Yahoo (YHOO), down 0.6% after RBC Capital downgraded its rating on the stock to Sector Perform from Outperform, saying the risk/reward is less attractive following Alibaba's (BABA) initial public offering... HB Fuller (FUL), down 15% after reporting quarterly results and guidance that missed analyst estimates... Omnova Solutions (OMN), down 10.8% after its Q3 adjusted EPS missed expectations... Pacira Pharmaceuticals (PCRX), down 9.2% after receiving an FDA warning letter over certain promotional materials on Exparel.
08:01 EDTPFEPfizer completes acquisition of InnoPharma
Subscribe for More Information
07:02 EDTLHLabCorp acquires LipoScience
LabCorp (LH) and LipoScience (LPDX) announced that they entered into a definitive merger agreement under which LabCorp would acquire LipoScience for a purchase price of $5.25 per share in cash, or a transaction value of $85.3M which represents a total enterprise value of approximately $63M. The Board of Directors of LipoScience has unanimously approved the agreement and recommended approval of the transaction by LipoScienceís stockholders. The transaction is subject to customary closing conditions including the expiration or early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and approval by LipoScienceís stockholders. The transaction is expected to close in Q4.
07:00 EDTLHLabCorp acquires LipoScience for $5.25 per share in cash
06:58 EDTLHLabCorp agrees to acquire LipoScience for $5.25 per share
Subscribe for More Information
06:56 EDTLHLabCorp to acquire LipoScience for $5.25 per share in all cash transaction
06:56 EDTLHLabCorp agrees to acquire LipoScience for $5.25 per share
Subscribe for More Information
September 24, 2014
15:34 EDTCYTXCytori Therapeutics restructuring, new alignment positive, says Maxim
Subscribe for More Information
06:14 EDTPFEPfizer, Actavis takeover talks ended last week, WSJ reports
Subscribe for More Information
September 23, 2014
16:20 EDTPFEOn The Fly: Closing Wrap
Stocks on Wall Street were lower after the U.S. took new action to clamp down on tax inversion deals and led airstrikes against Islamic State militants in Syria, while Europe reported weaker than expected manufacturing data. ECONOMIC EVENTS: In the U.S., the FHFA's home price index rose 0.1% in July to 212.7, missing expectations for an increase of 0.5%. Markit's preliminary manufacturing Purchasing Managers' Index for September came in at 57.9, slightly below the consensus forecast for a 58.0 reading. In China, HSBC's flash manufacturing PMI rose to 50.5 from a final reading of 50.2 in August, better than expectations. In Europe, Markit's composite flash PMI for the eurozone dipped to a nine-month low of 52.3, missing expectations for it to hold steady with its 52.5 reading for August. COMPANY NEWS: The shares of a number of companies that have announced or been speculated as targets in tax inversion deals fell after the U.S. Treasury last night issued new regulations that will make such deals less attractive. AstraZeneca (AZN), which has previously turned down an offer to be acquired by the U.S.'s Pfizer (PFE), sank $3.54, or 4.74%, to $71.13 despite a Bloomberg report that said Pfizer is still considering pursuing a deal with the U.K. drugmaker. AbbVie (ABBV), which has a deal in progress to acquire Shire (SHPG) and thus move its tax domicile to Ireland, fell $1.15, or 1.96%, to $57.56, while Shire shares slid $5.56, or 2.17%, to $250.74. Medtronic (MDT), which is pursuing its own inversion deal with Covidien (COV), dropped $1.90, or 2.88%, to $64.08. MAJOR MOVERS: Among the notable gainers was Herbalife (HLF), which rose $3.88, or 9.65%, to $44.09, bouncing back from a pullback yesterday that had been attributed to rumors of Carl Icahn selling out of his stake in the company. Also higher was Plug Power (PLUG), which rose 40c, or 9.57%, to $4.58 after the company's CEO gave FY15 revenue guidance that was above the consensus Street view in an interview with the Albany Business Review. Among the noteworthy losers was Ascena Retail (ASNA), which dropped $2.78, or 16.82%, to $13.75 after the apparel retailer's fourth quarter results and fiscal 2015 profit outlook trailed analysts' consensus estimates. Also lower were shares of used car retailer CarMax (KMX), which fell $5.01, or 9.49%, to $47.80 after the company reported sluggish comparable used car sales in its second quarter. INDEXES: The Dow declined 116.81, or 0.68%, to 17,055.87, the Nasdaq dropped 19.00, or 0.42%, to 4,508.69, and the S&P 500 fell 11.52, or 0.58%, to 1,982.77.
14:23 EDTPFEPfizer approached Actavis about takeover, Bloomberg reports
Pfizer (PFE) approached Actavis (ACT) to express interest in an acquisition, Bloomberg reports, citing people with knowledge of the matter said. No formal talks are ongoing and Pfizer has not made an offer, Bloomberg adds. Pfizer is still considering pursuing a deal with AstraZeneca (AZN) as well as other options, the report says. Shares of Actavis rallied 3% to $243.06 following the story. Reference Link
14:12 EDTPFEPfizer weighing options including AstraZeneca bid, Bloomberg says
Subscribe for More Information
14:12 EDTPFEPfizer approached Actavis about takeover, Bloomberg reports
13:44 EDTPFEISI Group to hold a webinar
Subscribe for More Information
12:11 EDTPFEOn The Fly: Midday Wrap
Stocks on Wall Street were mixed and little changed at midday, amid new rules from the Obama administration on tax inversions and manufacturing data from around the globe. ECONOMIC EVENTS: In the U.S., the FHFA's home price index rose 0.1% in July to 212.7, missing expectations for a rise of 0.5%. Markit's preliminary manufacturing Purchasing Managers' Index for September came in at 57.9, slightly below the consensus forecast for a 58.0 reading. The Richmond Fed manufacturing index for September rose to 14, beating expectations for it to have dropped two points to 10. In China, HSBC's flash manufacturing Purchasing Managers' Index rose to 50.5 from a final reading of 50.2 in August, better than expectations. In Europe, Markit's composite flash PMI for the eurozone dipped to a nine-month low of 52.3, missing expectations for it to hold steady at the 52.5 seen in August. COMPANY NEWS: Shares of several companies, including a number in the pharmaceutical industry, are lower in early trading after the Treasury Department announced new regulations yesterday night that aim to make it tougher for U.S. companies to lower their tax burdens via mergers with foreign companies, otherwise known as "inversions." Among the stocks that moved lower after the new rules were announced was Astrazeneca (AZN), which had previously been a target of Pfizer (PFE) and fell about 4% near midday. Also lower were shares of both Shire (SHPG), which fell 2%, and Abbvie (ABBV), which dropped 1.6%, as the two have previously agreed to merge in a tax inversion deal. Medtronic (MDT) and Covidien (COV), which similarly agreed to an inversion merger, were down 3.3% and 2.7%, respectively. MAJOR MOVERS: Among the notable gainers was Salix Pharmaceuticals (SLXP), which rose more than 5% after The Wall Street Journal reported that Allergan (AGN) is in advanced talks on a deal to buy the company. Shares of Allergan were also up nearly 3% near midday, as the Journal also reported that Allergan rejected a recent buyout offer from Actavis (ACT). Among the noteworthy losers was Ascena Retail (ASNA), which dropped 16% after the apparel retailer's fourth quarter results and fiscal 2015 profit outlook trailed analysts' consensus estimates. Also lower following its own earnings report was auto retailer CarMax (KMX), which fell over 9%. INDEXES: Near midday, the Dow was down 32.91, or 0.19%, to 17,139.77, the Nasdaq was up 2.90, or 0.06%, to 4,530.59, and the S&P 500 was down 2.29, or 0.11%, to 1,992.00.
10:54 EDTPFEStocks, analysts react to Treasury inversion crackdown
Subscribe for More Information
09:00 EDTLLYBofa/Merill special situations team to hold an analyst/industry conference call
Subscribe for More Information
06:40 EDTPFEPiper says don't dismiss potential Pfizer bid for Actavis
Piper Jaffray says it would not be dismissive of Pfizer (PFE) as a potential acquirer of Actavis (ACT). Piper believes Pfizer's public M&A comments are supportive of Actavis' exposure to complex generics and emerging markets. The firm views Actavis shares as attractively valued, irrespective of the acquisition chatter. It reiterates an Overweight rating on the stock with a $280 price target.
September 22, 2014
08:12 EDTCYTXCytori sees 'modest overall revenue growth' in FY14
The company said, "Despite the impact of the cost reduction efforts, Cytori continues to anticipate modest overall revenue growth in 2014. Overall revenue growth in 2015 and 2016 will likely continue to be modest but should show a positive contribution margin beginning in 2015 based on the combination of recent expense reductions and forecasted increases in sales to Lorem Vascular and other partners, as well as through Cytoriís leaner direct sales teams in both Japan and Europe." FY14 revenue consensus $15.06M.
08:05 EDTCYTXCytori announces restructuring, cost reduction plans
Subscribe for More Information
07:21 EDTLLYEBD Group to hold a conference
Subscribe for More Information
September 19, 2014
16:00 EDTPFEOptions Update; September 19, 2014
Subscribe for More Information
10:07 EDTPFEHigh option volume stocks
Subscribe for More Information
September 18, 2014
15:57 EDTLLYFDA approves Trulicity with boxed warning, post-marketing study requirements
Subscribe for More Information
15:55 EDTLLYFDA approves Eli Lilly type 2 diabetes drug
Subscribe for More Information
11:15 EDTLLYRepros sinks after panel backs tests for testosterone therapies
Subscribe for More Information
08:12 EDTLLYEli Lilly's Cyramza for gastric cancer shows positive Phase 3 results
Eli Lilly announced results of the global Phase III trial of ramucirumab - CYRAMZA - in combination with paclitaxel in patients with advanced gastric cancer or gastroesophageal junction adenocarcinoma. The addition of ramucirumab to paclitaxel showed a statistically significant improvement in median overall survival, meeting its primary endpoint; it also met secondary endpoints of progression-free survival and objective response rate. Data from the trial were first presented in January. Ramucirumab has now been the focus of two positive Phase III gastric cancer trials that have demonstrated statistically significant improvements in both overall survival and progression-free survival.
08:01 EDTLLYDow AgroSciences announces R&D agreement with Lilly's Elanco
Two Indiana agricultural companies, Elanco, the animal health division of Eli Lilly and Company (LLY), and Dow AgroSciences LLC, a wholly owned subsidiary of The Dow Chemical Company (DOW), are announcing a strategic research and development agreement that will focus on developing integrated solutions to enable livestock producers to increase meat and milk production to meet the demands of the growing global population.
06:10 EDTLLYFDA panel votes 20-1 to study changes to testosterone therapies
Subscribe for More Information
September 17, 2014
07:47 EDTFLDMFluidigm shares recommended at Maxim
Subscribe for More Information
07:43 EDTPFEBofA/Merrill to hold a conference
Subscribe for More Information
07:39 EDTLLYMorningstar to hold a conference
Management Behind the Moat Conference to be held in Chicago on September 17-18.
September 16, 2014
12:35 EDTLLYDenovo Biopharma acquires late-stage oncology drug enzastaurin from Eli Lilly
Subscribe for More Information
11:51 EDTPFEOECD looks to close tax loopholes with new proposals
Subscribe for More Information
08:04 EDTLHLabCorp, ARCA Biopharma present GENETIC-AF poster at HFSoA meeting
Subscribe for More Information
07:31 EDTLLYEuropean Association for Study of Diabetes to hold annual meeting
50th Annual Meeting of EASD to be held in Vienna, Austria on September 15-19.
07:19 EDTPFECompanies' share buybacks at fasttest clip since 2007, WSJ reports
Companies are buying back their own shares at its fastest pace since the financial crisis to fuel a stock rally, reports the Wall Street Journal. According to Birinyi Associates, companies have bought back $338.3B of stock in 1H14, the most since 2007. Citing an analysis by Barclays, companies with the largest buyback programs by dollar value have outperformed the broader market by 20% since 2008. Reference Link
07:02 EDTLLYEli Lilly and AstraZeneca to co-develop and commercialize AZD3293
Subscribe for More Information
06:27 EDTLLYAstraZeneca, Eli Lilly to jointly develop, commercialize AZD3293
AstraZeneca (AZN) and Eli Lilly (LLY) announced an agreement to jointly develop and commercialize AZD3293, an oral beta secretase cleaving enzyme inhibitor currently in development as a potential treatment for Alzheimer's disease. AZD3293 has been shown in Phase I studies to significantly and dose-dependently reduce levels of amyloid beta in the cerebro-spinal fluid of Alzheimer's patients and healthy volunteers. AstraZeneca announced earlier in 2014 its plan to move AZD3293 into registration trials. Under the terms of the agreement, Lilly will pay AstraZeneca up to $500M in development and regulatory milestone payments. AstraZeneca expects to receive the first milestone payment of $50M in the 1H15. The companies will share all future costs equally for the development and commercialization of AZD3293, as well as net global revenues post-launch. AstraZeneca and Lilly aim to progress AZD3293 rapidly into a Phase II/III clinical trial in patients with early Alzheimer's disease. Lilly will lead clinical development, working with researchers from AstraZeneca's Innovative Medicines Unit for neuroscience, while AstraZeneca will be responsible for manufacturing. The companies will take joint responsibility for commercialization of AZD3293. The agreement is subject to customary terms and conditions. It will have no impact on AstraZeneca's 2014 Core Earnings per Share.
05:49 EDTPSTIPluristem Therapeutics pursues development strategy in Japan
Subscribe for More Information
<< 1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use